GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Additional Paid-In Capital

HLS Therapeutics (TSX:HLS) Additional Paid-In Capital : C$18.95 Mil(As of Mar. 2024)


View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Additional Paid-In Capital?


HLS Therapeutics's quarterly additional paid-in capital declined from Sep. 2023 (C$19.18 Mil) to Dec. 2023 (C$18.60 Mil) but then increased from Dec. 2023 (C$18.60 Mil) to Mar. 2024 (C$18.95 Mil).

HLS Therapeutics's annual additional paid-in capital increased from Dec. 2021 (C$15.00 Mil) to Dec. 2022 (C$18.78 Mil) but then declined from Dec. 2022 (C$18.78 Mil) to Dec. 2023 (C$18.60 Mil).

HLS Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for HLS Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Additional Paid-In Capital Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.17 14.59 15.00 18.78 18.60

HLS Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.54 18.80 19.18 18.60 18.95

HLS Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

HLS Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics (TSX:HLS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Additional Paid-In Capital
Comparable Companies
XCNQ:GDNS XCNQ:FFNT XCNQ:EPIC TSXV:RX NEOE:CBST XCNQ:INNO XCNQ:IAN XCNQ:JUSH TSXV:ZYUS TSXV:LOVE XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
HLTRF:USA
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
Website
https://www.hlstherapeutics.com
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.
Executives
Polar Asset Management Partners Inc. 10% Security Holder

HLS Therapeutics (TSX:HLS) Headlines

No Headlines